Wedbush Research Analysts Raise Earnings Estimates for ANRO

Alto Neuroscience, Inc. (NYSE:ANRO) – Wedbush raised their Q2 2025 earnings per share (EPS) estimates for Alto Neuroscience in a report issued on Thursday, May 15th. Wedbush analyst L. Chico now expects that the company will post earnings of ($0.68) per share for the quarter, up from their previous estimate of ($0.70). Wedbush currently has a “Neutral” rating and a $4.00 price target on the stock. The consensus estimate for Alto Neuroscience’s current full-year earnings is ($2.54) per share. Wedbush also issued estimates for Alto Neuroscience’s Q3 2025 earnings at ($0.70) EPS, Q4 2025 earnings at ($0.72) EPS, FY2025 earnings at ($2.63) EPS, FY2026 earnings at ($2.23) EPS and FY2029 earnings at ($2.87) EPS.

Alto Neuroscience (NYSE:ANRO) last announced its quarterly earnings data on Tuesday, May 13th. The company reported ($0.53) earnings per share for the quarter, beating the consensus estimate of ($0.59) by $0.06.

ANRO has been the subject of several other reports. HC Wainwright assumed coverage on Alto Neuroscience in a report on Monday, April 7th. They issued a “buy” rating and a $10.00 price objective for the company. William Blair reissued an “outperform” rating on shares of Alto Neuroscience in a report on Friday, March 21st. Three investment analysts have rated the stock with a hold rating and four have given a buy rating to the stock. According to data from MarketBeat, the company has a consensus rating of “Moderate Buy” and an average price target of $15.40.

Alto Neuroscience Stock Up 14.6%

Shares of Alto Neuroscience stock opened at $2.91 on Monday. The company has a quick ratio of 13.09, a current ratio of 13.10 and a debt-to-equity ratio of 0.05. The firm has a market cap of $78.78 million, a P/E ratio of -1.24 and a beta of 1.87. Alto Neuroscience has a fifty-two week low of $1.60 and a fifty-two week high of $17.55. The business has a 50-day moving average price of $2.35 and a 200 day moving average price of $3.41.

Hedge Funds Weigh In On Alto Neuroscience

Institutional investors have recently made changes to their positions in the stock. Wells Fargo & Company MN grew its holdings in shares of Alto Neuroscience by 40.0% during the fourth quarter. Wells Fargo & Company MN now owns 10,989 shares of the company’s stock valued at $46,000 after purchasing an additional 3,139 shares during the last quarter. Deutsche Bank AG grew its holdings in shares of Alto Neuroscience by 31.3% during the fourth quarter. Deutsche Bank AG now owns 15,210 shares of the company’s stock valued at $64,000 after purchasing an additional 3,629 shares during the last quarter. Skandinaviska Enskilda Banken AB publ bought a new position in shares of Alto Neuroscience during the fourth quarter valued at approximately $74,000. Jane Street Group LLC grew its holdings in shares of Alto Neuroscience by 72.0% during the fourth quarter. Jane Street Group LLC now owns 18,600 shares of the company’s stock valued at $79,000 after purchasing an additional 7,783 shares during the last quarter. Finally, AQR Capital Management LLC bought a new position in shares of Alto Neuroscience during the first quarter valued at approximately $52,000.

Alto Neuroscience Company Profile

Alto Neuroscience, Inc operates as a clinical-stage biopharmaceutical company in the United States. Its product pipeline comprising ALTO-100, which is in phase 2b clinical trial for the treatment of patients with major depressive disorder (MDD); and which is in phase 2a clinical trial for the treatment of post-traumatic stress disorder.